Skip to main content

As Houston Life Sciences Sector Heats Up, Developers Delivering On Needed Space

Published Jun 07, 2022 by A.J. Mistretta

levit green.jpg

A rendering of Levit Green

Texas A&M TMC.jpg

A rendering of Texas A&M's Innovation Plaza

A life sciences real estate building boom is sweeping the nation, driven by sharp increases in health-related VC funding, promising new therapies from pharmaceutical companies and a shortage of available space, particularly in emerging markets. 

Investment in U.S. life sciences real estate increased 62% in 2021, according to a report from commercial real estate firm CBRE. Investment in the sector has grown by 111% since 2018 and another 10% increase is forecast for 2022, with much of that new investment going to ground-up development. 

Industry watchers are pointing to Houston as one rapidly evolving market where proximity to the world’s largest medical center and a diverse and educated population are fueling interest from established life sciences and biotech companies aiming to grow, just as new startups hatched out of local research institutions look to scale. 

Life sciences/health care led among the local sectors in venture capital funding for four of the last five years and accounted for 26% of all VC funding in the market in 2021. Promising startups and new technology are adding to an already robust market with more than 1,700 life sciences firms, hospitals and research institutions currently operating in the region. Big players such as Abbott, Bayer, Merck and Novartis already have a strong local presence. 

Commercial space for life sciences companies, including lab space, offices and more, has been scarce, but a series of projects near Houston’s core are underway to satisfy growing demand. At the same time, a mounting cohort of companies are looking outside the urban center for affordable space in promising suburban districts like The Woodlands, Pearland, Sugar Land and League City.  

Here’s an updated look at several major projects: 

TMC3

Texas Medical Center is slated to deliver the first phase of its ambitious 37-acre TMC3 collaborative research campus in 2023. The 250,000-square-foot Collaborative Building will include a large-scale research lab, office space, 7,000-square-foot atrium and more. A hotel and conference center, residential and retail space, as well as six additional industry and research buildings are included in the project’s master plan. TMC is working in collaboration with other founding institutions to create the campus centered around a series of parks in the shape of a double helix. The partners include the University of Texas MD Anderson Cancer Center, Texas A&M University Health Sciences Center and the University of Texas Health Science Center at Houston. Learn more

Levit Green 

Hines is slated to complete the first phase of its 53-acre Levit Green life sciences campus this year. The initial five-story building will create 294,000 square feet of space overlooking a plaza and a manmade lake. In time, Hines and its project partners 2ML Real Estate and Harrison Street hope to create roughly 4 million square feet of development on the site located between Hermann Park and Texas 288. Learn more

Texas A&M Innovation Plaza 

Texas A&M University and its development partners Medistar Corp. and Healthcare Trust of America are well underway on Texas A&M Innovation Plaza, a new five-acre campus within the Texas Medical Center and adjacent to the TMC Transition Station. The project is centered around a common green space will include three towers: EnMed Tower, an 18-story, 280,000-square-foot academic building anchored by the university’s Engineering-Medicine (EnMed) program; Life Tower, a 19-story, student housing building; and the 30-story Horizon Tower, which will include 17 floors of life sciences, dry and wet labs, restaurants, retail, and medical office space atop a 2,600-space parking garage. Horizon Tower is slated for completion in Q1 2024. Learn more
 

Learn more about the life sciences industry in Houston.

Related News

Life Sciences

MD Anderson, Rice University Launch New Collaborative to Advance Cancer Research

7/2/24
A new collaboration between The University of Texas MD Anderson Cancer Center and Rice University promises to drive industry growth and advance life-saving technologies through the newly established Cancer Bioengineering Collaborative. The initiative will help foster collaboration between the two institutions on fundamental and translational cancer research, develop new technologies for cancer detection and therapy, and secure external funding in support of further research and training. Rice researcher and Cancer Prevention and Research Institute of Texas (CPRIT) scholar Gang Bao and MD Anderson’s Dr. Jeffrey Molldrem will lead the hub.  “From fundamental discoveries in cancer science, tumor immunology and patient care to innovative engineering advances in drug delivery systems, nanostructures and synthetic biology, there is great potential for enabling cross-disciplinary collaboration to develop new technologies and approaches for detecting, monitoring and treating cancer,” Molldrem, chair of Hematopoietic Biology & Malignancy at MD Anderson, said in a release. “Our goal is to bridge the gap between bioengineering and cancer research to create transformative solutions that significantly improve patient outcomes.” The collaborative will also host monthly seminars focused on cancer bioengineering, annual retreats to highlight research and international leaders in cancer and bioengineering. Five research areas will be at the core of the hub’s work: Cell therapies: Developing more effective cell-based immunotherapies, including chimeric antigen receptor- and T cell receptor-based approaches. Nanotechnologies: Using nanoparticles for targeted cancer detection and therapy. Cancer vaccines: Incorporating advanced biomaterials, synthetic biology and nanoparticle delivery systems to develop therapeutic cancer vaccines. Artificial intelligence: Leveraging advanced computing tools for high-precision analysis of samples to identify new targets and inform therapeutic design. Molecular imaging: Deploying advanced molecular imaging techniques to enhance diagnostic and therapeutic tools. A seed grant program will also be established to fund research projects in the early stages of development. The partnership between Rice and MD Anderson is a testament to how the greater Houston region is committed to advancing the life sciences and biotech industry. The region has seen major new life science developments come online recently, including Levit Green, TMC Helix Park and The Alexandria Center for Advanced Technologies in The Woodlands.   
Read More
Life Sciences

The Woodlands Innovation District Aims to Attract Life Sciences Companies

6/28/24
A new district in The Woodlands hopes to expand on the area’s resurgence in life sciences developments.    Post pandemic, life sciences companies have been establishing facilities in The Woodlands, particularly along Research Forest Drive. And now, Developers Howard Hughes and Vitrian are building upon that growth by adding an additional 86.3 acres for future development, aiming to attract more biomanufacturing companies to the area. The duo has dubbed the area The Woodlands Innovation District.  “This joint venture further diversifies the innovative industries that are represented in The Woodlands with the advancement of life science,” said Jim Carman, President of the Houston Region for The Howard Hughes Corporation in a statement. “The Woodlands continues to attract companies from a variety of industries seeking a highly-skilled talent pool, business-friendly environment, and high quality of life for their employees.”  The district joins the area’s cluster of existing life sciences companies, such as Millipore Sigma and VGXI. Cellipont Bioservices, a San Diego-based cell therapy contract development and manufacturing organization, recently opened a 76,000-square-foot facility in the area. The facility is dedicated to cell therapies and serves as the company's new headquarters.  Cellipont’s move to the greater Houston region, announced in 2022, kickstarted a surge in life sciences activity in The Woodlands. Bionova Scientific, another California-based biotech company, recently announced plans to expand into the area, with a 100,000-square-foot manufacturing and research facility. The company, which produces materials used by cancer-fighting cell therapy companies, is expected to begin operations at the new location in 2025.  Nearby, Nurix Therapeutics, a clinical-stage biopharmaceutical company based in San Francisco, has relocated to the Alexandria Center for Advanced Technologies. This 12-acre life sciences campus, formerly the Lexicon Pharmaceuticals site, was inaugurated last year with support from Lexicon’s Founder and CEO and now Nurix's Chief Executive Officer, Arthur Sands. Backed by California-based real estate firm Alexandria Real Estate Equities, the campus is still being built out, with the goal of becoming a smaller version of The Texas Medical Center.   These recent developments have established The Woodlands as a leader in life sciences in the region. According to CBRE’s 2023 U.S. Life Sciences Outlook, The Woodlands accounted for 60% of the Houston region’s life sciences lease transactions in 2022.  The Woodlands Innovation District will encompass five sites, each providing tenant facilities ranging from 40,000 to over 200,000 square feet. These sites will offer build-to-suit shell spaces, anticipated to be move-in ready by Spring 2025.  Learn more about Houston’s life sciences and biotechnology industries. 
Read More

Related Events

Health Care

Life Sciences and Biotechnology Forum

Finding solutions to the problems that matter most is baked into Houston’s DNA. As the Third Coast for Life Sciences, the region’s world-class medical centers, research institutes and private companies are taking on…

Learn More
Learn More
Executive Partners